Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Solid Tumors 1Neoplasms 1Advanced and/or Metastatic Solid Tumours 1Advanced Esophageal 1Advanced Cancer 1

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × nimotuzumab × Clear all
NCT07053735 2025-07-08

An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer

Peking University First Hospital

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡